IBEX Therapeutics creates plant‑derived topical therapies—sprays, gels, and sticks—that combine a standardized Epilobium lanceolatum extract rich in oenothein B with oral probiotic strains to prevent and treat oral mucositis in cancer patients. The formulations aim to reduce inflammation, pain, and secondary Candida infections, helping patients maintain their chemotherapy or radiotherapy schedules.
Funding
Funding not disclosed
Founders
Product
Problem
Oral mucositis and related oral complications affect 40‑60% of cancer patients undergoing chemotherapy or radiotherapy, causing painful inflammation, ulcerations, and candidiasis that can interrupt treatment and diminish quality of life. Existing local therapies (e.g., bicarbonate rinses, benzydamine, photobiomodulation) have limited efficacy, tolerability, or cost‑effectiveness, and no standard‑of‑care preventive treatment is established.
Solution
IBEX Therapeutics develops plant‑derived biologic therapies to prevent and treat oral mucositis in oncology patients. Their platform delivers topical oral formulations—sprays, gels, and sticks—containing Swiss‑grown organic botanicals, notably a proprietary Epilobium lanceolatum extract rich in oenothein B, and targeted oral probiotics. The botanical extract provides anti‑inflammatory, antioxidant, and anti‑Candida adhesion activity, while the probiotic component supports a balanced oral microbiome. Formulations are designed for easy self‑administration, clinical safety, and microbiological stability, aiming to reduce inflammation, alleviate pain, and lower the incidence of secondary candidiasis, thereby supporting uninterrupted cancer therapy.
Target Audience
Primary customers are oncology clinics, hospitals, and dental care providers treating patients receiving mucitogenic chemotherapy or radiotherapy, as well as pharmaceutical distributors targeting the oral supportive care market.
Features
- Organic Epilobium lanceolatum extract cultivated in Valais, standardized for high oenothein B content with demonstrated anti‑Candida adhesion properties
- Combination of phytotherapeutic actives and clinically validated oral probiotic strains to modulate inflammation and microbiota
- Multiple dosage forms (spray, gel, stick) optimized for rapid mucosal coverage and patient convenience
- Clinically tested skin compatibility and 28‑day microbiological stability of the formulations
- Scalable manufacturing using Swiss‑certified organic agriculture and GMP‑compliant extraction processes